JP2008513413A5 - - Google Patents

Download PDF

Info

Publication number
JP2008513413A5
JP2008513413A5 JP2007531758A JP2007531758A JP2008513413A5 JP 2008513413 A5 JP2008513413 A5 JP 2008513413A5 JP 2007531758 A JP2007531758 A JP 2007531758A JP 2007531758 A JP2007531758 A JP 2007531758A JP 2008513413 A5 JP2008513413 A5 JP 2008513413A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
group
alkynyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007531758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513413A (ja
Filing date
Publication date
Priority claimed from GB0420719A external-priority patent/GB0420719D0/en
Application filed filed Critical
Publication of JP2008513413A publication Critical patent/JP2008513413A/ja
Publication of JP2008513413A5 publication Critical patent/JP2008513413A5/ja
Pending legal-status Critical Current

Links

JP2007531758A 2004-09-17 2005-09-16 新規なチエノ−ピリジンおよびチエノ−ピリミジン誘導体およびｍｇｌｕｒ２−受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 Pending JP2008513413A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0420719A GB0420719D0 (en) 2004-09-17 2004-09-17 Novel allosteric modulators
PCT/EP2005/054635 WO2006030031A1 (en) 2004-09-17 2005-09-16 Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors

Publications (2)

Publication Number Publication Date
JP2008513413A JP2008513413A (ja) 2008-05-01
JP2008513413A5 true JP2008513413A5 (enExample) 2008-11-06

Family

ID=33306765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531758A Pending JP2008513413A (ja) 2004-09-17 2005-09-16 新規なチエノ−ピリジンおよびチエノ−ピリミジン誘導体およびｍｇｌｕｒ２−受容体のポジティブアロステリックモジュレーターとしてのそれらの使用

Country Status (9)

Country Link
US (1) US20070275984A1 (enExample)
EP (1) EP1799687A1 (enExample)
JP (1) JP2008513413A (enExample)
CN (1) CN101061122A (enExample)
AU (1) AU2005284097A1 (enExample)
CA (1) CA2580656A1 (enExample)
GB (1) GB0420719D0 (enExample)
TW (1) TW200634016A (enExample)
WO (1) WO2006030031A1 (enExample)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP1513516B1 (en) 2002-06-06 2008-12-03 Boehringer Ingelheim Pharmaceuticals Inc. SUBSTITUTED 3-AMINO-THIENO(2,3-b) PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
US7276519B2 (en) 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
PT1730146E (pt) 2004-03-30 2011-07-11 Vertex Pharma Azaindoles úteis como inibidores de jak e outras proteínas quinases
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
NZ601687A (en) 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
MX2008010611A (es) 2006-02-17 2008-11-12 Pfizer Ltd Derivados de 3-desazapurina como moduladores de receptores similares a toll.
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
US7592353B2 (en) 2006-06-06 2009-09-22 Boehringer Ingelheim International Gmbh Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
DK2583970T3 (en) * 2006-08-02 2015-11-16 Cytokinetics Inc Certain chemical entities, compositions, and methods comprising imidazopyrimidines
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
CN105693730A (zh) 2006-10-19 2016-06-22 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
CA2673472A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo) [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
WO2008092862A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092861A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
NZ579431A (en) * 2007-03-09 2012-04-27 Sanofi Aventis Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
EP2069324B1 (en) * 2007-03-20 2013-07-31 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
WO2008121333A1 (en) * 2007-03-30 2008-10-09 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
WO2009025358A1 (ja) 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
TW200942549A (en) 2007-12-17 2009-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
US7989469B2 (en) * 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US7998976B2 (en) * 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
ES2530200T3 (es) 2008-02-06 2015-02-27 Senomyx, Inc. Composiciones edulcorantes y métodos para obtenerlas
SG190667A1 (en) 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
PL2308877T3 (pl) 2008-08-05 2014-07-31 Daiichi Sankyo Co Ltd Pochodne imidazopirydyn-2-onu
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
TWI389913B (zh) * 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
CN102216276A (zh) 2008-09-11 2011-10-12 辉瑞大药厂 取代的杂芳基物
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
UA103351C2 (uk) 2008-12-05 2013-10-10 Ебботт Леборетріз ПОХІДНІ ТІЄНО[3,2-c]ПІРИДИНУ ЯК ІНГІБІТОРИ КІНАЗ ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ РАКУ
CA2786715C (en) * 2009-01-16 2019-05-21 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
JP5086480B2 (ja) 2009-03-11 2012-11-28 ファイザー・インク グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
BRPI1010831A2 (pt) * 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2764885C (en) 2009-06-08 2018-05-15 Takeda Pharmaceutical Company Limited Dihydropyrrolonaphtyridinone compounds as inhibitors of jak
PH12015501678B1 (en) 2009-06-17 2022-07-06 Vertex Pharma Inhibitors of influenza viruses replication
WO2010148074A1 (en) * 2009-06-19 2010-12-23 Astrazeneca Pharmaceuticals The use of metabotropic glutamate receptor potentiators for reducing nicotine dependence
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
CA2778615C (en) 2009-10-26 2019-04-23 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
PT3029039T (pt) 2010-05-17 2017-11-28 Forum Pharmaceuticals Inc Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
AU2011311867A1 (en) 2010-10-08 2013-04-18 Abbvie Inc. Furo(3,2-d)pyrimidine compounds
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CN103748085A (zh) 2011-06-09 2014-04-23 诺华股份有限公司 杂环磺酰胺衍生物
ES2548414T3 (es) 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
WO2013010015A2 (en) 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
EP2734186B1 (en) 2011-07-22 2018-09-12 GlaxoSmithKline LLC Composition
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
PL3513793T3 (pl) 2011-09-02 2021-09-20 Incyte Holdings Corporation Heterocykloaminy jako inhibitory pi3k
KR102063098B1 (ko) 2011-10-03 2020-01-08 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 암 치료를 위한 피롤로피리미딘 화합물
US9493466B2 (en) 2011-10-19 2016-11-15 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
ES2406635B1 (es) * 2011-12-02 2014-06-11 Cartonajes Bernabeu, S.A. Sistema paletizador para lineas de alimentacion de embalajes.
ES2411804B1 (es) * 2011-12-02 2014-05-12 Universidad De Zaragoza Compuestos inhibidores de la agregación del péptido beta amiloide.
NZ628410A (en) 2012-02-24 2016-03-31 Signal Pharm Llc Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2846796A4 (en) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION
CN104302627A (zh) 2012-05-22 2015-01-21 北卡罗来纳大学教堂山分校 用于治疗癌症的嘧啶化合物
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
CA2880576A1 (en) 2012-08-24 2014-02-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2890198A1 (en) 2012-11-20 2014-05-30 Diane Mary Coe Novel compounds
NZ707319A (en) 2012-11-20 2019-09-27 Glaxosmithkline Llc 5h-pyrrolo[3,2-d]pyrimidin-4-amine compounds and their use in the treatment of allergic diseases and other inflammatory conditions
RU2643371C2 (ru) 2012-11-20 2018-02-01 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
US9346812B2 (en) 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
KR20150119370A (ko) 2013-02-19 2015-10-23 화이자 인코포레이티드 Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
NZ629230A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NZ629469A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
US9908893B2 (en) 2013-06-11 2018-03-06 Latvian Institute Of Organic Synthesis Thieno [2,3-b] pyridines as multidrug resistance modulators
PL3010503T3 (pl) 2013-06-21 2020-08-24 Zenith Epigenetics Ltd. Nowe bicykliczne inhibitory bromodomen
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
EP3027604B1 (en) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
TWI648281B (zh) * 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
JP6615755B2 (ja) 2013-11-13 2019-12-04 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルスの複製の阻害剤
AU2014348752C1 (en) 2013-11-13 2019-11-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
US9108953B2 (en) 2013-11-26 2015-08-18 Gilead Sciences, Inc. Quinoline derivatives as bromodomain inhibitors
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US9815841B2 (en) 2014-01-29 2017-11-14 Glaxosmithkline Intellectual Property Development Limited Compounds
CA2937431A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2015157123A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
WO2016020786A1 (en) 2014-08-06 2016-02-11 Pfizer Inc. Imidazopyridazine compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
RS63963B1 (sr) 2015-02-27 2023-03-31 Incyte Holdings Corp Postupak pripreme pi3k inhibitora
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
KR101816233B1 (ko) * 2015-10-29 2018-01-08 삼성에스디아이 주식회사 유기 광전자 소자용 화합물, 유기 광전자 소자 및 표시 장치
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
WO2017207340A1 (de) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
RU2019108280A (ru) 2016-08-24 2020-09-25 Аркьюл, Инк. Аминопирролопиримидиноновые соединения и способы их применения
WO2018060174A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
MX390582B (es) 2016-12-28 2025-03-20 Dart Neuroscience Llc Star Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2)
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
KR102794907B1 (ko) 2017-11-27 2025-04-14 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
TWI853814B (zh) 2018-05-31 2024-09-01 南韓商Ｃ＆Ｃ新藥研究所 雜環衍生物及其用途
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2020412779A1 (en) * 2019-12-23 2022-06-23 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators and uses thereof
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
JP7588224B2 (ja) 2020-10-05 2024-11-21 エンライブン インコーポレイテッド Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
JP7782035B2 (ja) 2021-11-09 2025-12-08 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DD245667A1 (de) * 1985-09-20 1987-05-13 Univ Halle Wittenberg Verfahren zur herstellung von 4-(alkoxycarbonylalkyl-bzw.-arylamino)-thieno 2,3-d pyrimidinen
AU626418B2 (en) * 1989-05-16 1992-07-30 Merrell Pharmaceuticals Inc. Excitatory amino acid antagonists
AU651337B2 (en) * 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
DE19632423A1 (de) * 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
JP4166296B2 (ja) * 1997-04-25 2008-10-15 塩野義製薬株式会社 ドーパミン受容体拮抗作用を有する化合物
DE19752952A1 (de) * 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
BR9916746A (pt) * 1999-06-03 2005-01-11 Abbott Lab Compostos anti-inflamatórios que inibem adesão de célula
AU1071301A (en) * 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
US6800651B2 (en) * 2000-02-03 2004-10-05 Eli Lilly And Company Potentiators of glutamate receptors
JP2002308882A (ja) * 2001-02-08 2002-10-23 Yamanouchi Pharmaceut Co Ltd チエノピリミジン誘導体
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
DE602004012083T2 (de) * 2003-04-15 2009-04-23 Astrazeneca Ab Neue Verbindungen, die als Verstärker von Glutamatrezeptoren dienen
EP1675861B1 (en) * 2003-08-29 2015-12-23 Vernalis (R&D) Ltd. Pyrimidothiophene compounds
EP1778093B1 (en) * 2004-08-11 2013-04-03 Koninklijke Philips Electronics N.V. Ultrasonic diagnosis of ischemic cardiodisease

Similar Documents

Publication Publication Date Title
JP2008513413A5 (enExample)
JP2008513414A5 (enExample)
AU2001294117B2 (en) Combination use of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of cognitive disorders
TWI736642B (zh) ５，７－二氫－吡咯並－吡啶衍生物類
JP2003520272A5 (enExample)
JP2009530248A5 (enExample)
TWI680128B (zh) 二氫吡咯並吡啶衍生物
JP2005047930A5 (enExample)
ES2585262T3 (es) Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
JP5934403B2 (ja) ５，６−ジヒドロ−１ｈ−ピリジン−２−オン化合物
ME01488B (me) Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842
AU2001294117A1 (en) Combination use of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of cognitive disorders
KR20190080897A (ko) 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
SG178832A1 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
JP2012526736A5 (enExample)
JP2009520685A5 (enExample)
MX2007012637A (es) Compuestos espiroheterociclicos y sus usos como agentes terapeuticos.
JP2009536155A5 (enExample)
AU2016204723A1 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
KR20080093453A (ko) 4-아실아미노피리딘 유도체 매개된 신경조직발생
US20080096867A1 (en) Imidazo[1,2-A] Pyridine Anxiolytics
RU2212237C2 (ru) Средство для лечения нейрогенного воспаления
CA2700539A1 (en) Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity
US9656984B2 (en) PI3K/AKT/mTOR inhibitors and pharmaceutical uses thereof
RU2005107588A (ru) Антидепрессанты-пиперидиновые производные конденсированных с гетероциклами бензодиоксанов